{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:30:15Z","timestamp":1767357015667,"version":"3.48.0"},"reference-count":69,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Over the past decade, significant progress has been made in the treatment of chronic hepatitis C virus (HCV) infection. The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of HCV infection, offering nearly 100% efficacy. Furthermore, additional therapeutic regimens with pangenotypic efficacy have been registered. These drugs are also characterized by a few adverse events and good treatment tolerance. As DAA therapy is now accessible to virtually all patients, including those with multimorbidity who often take multiple medications, drug interactions (DDIs) have become a significant clinical challenge. One of the groups of patients who are frequently infected with HCV is those with mental disorders. Due to frequently overlapping metabolic pathways, DDIs can occur, affecting the effectiveness of both psychiatric and antiviral therapy. Knowledge of these interactions is crucial in these cases and influences patient management. This paper discusses the most significant interactions between pangenotypic DAA regimens and psychotropic medications.<\/jats:p>","DOI":"10.3390\/ph19010087","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:23:44Z","timestamp":1767356624000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-8519","authenticated-orcid":false,"given":"Dorota","family":"Dybowska","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-0425","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Paw\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-6443","authenticated-orcid":false,"given":"Dorota","family":"Kozielewicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5114\/ceh.2020.98606","article-title":"Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020","volume":"6","author":"Halota","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.gastrohep.2022.06.001","article-title":"Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review","volume":"46","author":"Mena","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MEG.0000000000000855","article-title":"Chronic hepatitis C and individuals with a history of injecting drugs in Spain: Population assessment, challenges for successful treatment","volume":"29","author":"Roncero","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40121-015-0058-x","article-title":"A cross-sectional study comparing the frequency of drug interactions after adding simeprevir- or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected patients","volume":"4","author":"Patel","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40262-016-0407-2","article-title":"Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications","volume":"55","author":"Smolders","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/j.dld.2013.07.008","article-title":"The importance of drug-drug interactions in the DAA era","volume":"45","author":"Back","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/14740338.2012.631910","article-title":"Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions","volume":"11","author":"Magro","year":"2012","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_9","unstructured":"US Food and Drug Administration (2025, August 30). Preventable Adverse Reactions: A Focus on Drug Interactions, Available online: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/preventable-adverse-drug-reactions-focus-drug-interactions\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jppr.1101","article-title":"Multidrug interactions: The current clinical and pharmacovigilance challenge","volume":"45","author":"Roughead","year":"2015","journal-title":"J. Pharm. Pract. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/pr.113.007518","article-title":"Transporters and drug-drug interactions: Important determinants of drug disposition and effects","volume":"65","author":"Fromm","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/17512433.2014.910111","article-title":"Understanding and preventing drug-drug and drug-gene interactions","volume":"7","author":"Tannenbaum","year":"2014","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2174\/138945011795378504","article-title":"ABC multidrug transporters: Target for modulation of drug pharmacokinetics in drug-drug interactions","volume":"12","author":"Marquez","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"ref_16","unstructured":"European Medicines Agency (2025, August 30). Summary of Product Characteristics MAVIRET. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/maviret."},{"key":"ref_17","unstructured":"European Medicines Agency (2025, August 30). Summary of Product Characteristics EPCLUSA. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epclusa."},{"key":"ref_18","unstructured":"European Medicines Agency (2025, August 30). Summary of Product Characteristics SOVALDI. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sovaldi."},{"key":"ref_19","unstructured":"European Medicines Agency (2025, August 30). Summary of Product Characteristics VOSEVI. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vosevi."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical. Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives from the International Transporter Consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","unstructured":"Gabay, M., and Spencer, S.H. (2021). Drug Interactions: Scientific and Clinical Principles, American Psychiatric Publishing, Inc. (APPI). PSAP 2021 Book. 3 Chronic Conditions and Public Health."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.14218\/JCTH.2020.00034","article-title":"Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents","volume":"8","author":"Hong","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cld.668","article-title":"Drug-drug interactions in hepatitis C virus treatment: Do they really matter?","volume":"10","author":"Ahmed","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.18176\/resp.00095","article-title":"Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain","volume":"26","author":"Turnes","year":"2024","journal-title":"Rev. Esp. Sanid. Penit."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.dld.2023.01.140","article-title":"Use of psychiatric medication and drug interactions in patients with hcv infection treated with pangenotypic direct-acting antivirals","volume":"5","author":"Turnes","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_26","first-page":"1","article-title":"Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection","volume":"48","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_28","unstructured":"(2025, December 15). Available online: https:\/\/www.hep-druginteractions.org."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17425255.2017.1292253","article-title":"Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection","volume":"13","author":"Brieva","year":"2017","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-016-0648-2","article-title":"Sofosbuvir\/Velpatasvir: A review in chronic hepatitis C","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0376-8716(02)00188-6","article-title":"Clinical impairment of benzodiazepines\u2014Relation between benzodiazepine concentrations and impairment in apprehended drivers","volume":"68","author":"Bramness","year":"2002","journal-title":"Drug Alcohol. Depend."},{"key":"ref_32","unstructured":"European Medicines Agency (2025, August 30). Summary of Product Characteristics Olysio. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olysio."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sockalingam, S., Tseng, A., Giguere, P., and Wong, D. (2013). Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol., 13.","DOI":"10.1186\/1471-230X-13-86"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3748\/wjg.v29.i25.4085","article-title":"Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders","volume":"29","author":"Dybowska","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/hep.27920","article-title":"A clinician\u2019s guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection","volume":"63","author":"Dick","year":"2016","journal-title":"Hepatology"},{"key":"ref_36","unstructured":"Food and Drug Administration (2025, December 28). Prescribing Information Xanax, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/018276s059lbl.pdf."},{"key":"ref_37","unstructured":"Health Products Regulatory Authority (2025, December 28). Summary of Product Characteristics Lexotan. Available online: https:\/\/assets.hpra.ie\/products\/Human\/30761\/Licence_PA2239-008-001_07052020082419.pdf."},{"key":"ref_38","unstructured":"Electronic Medicines Compendium (2025, December 28). Summary of Product Characteristics Librium. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/1729\/smpc#gref."},{"key":"ref_39","unstructured":"(2021, December 28). Summary of Product Characteristics Dalpam. Available online: https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h118084_smpc_en.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.apsb.2014.02.001","article-title":"Comparative pharmacokinetics of zolpidem tartrate in five ethnic populations of China","volume":"4","author":"Guo","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0090-9556(24)15027-1","article-title":"Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism","volume":"27","author":"Becquemont","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_43","unstructured":"Food and Drug Administration (2025, December 28). Prescribing Information Cymbalta, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021427s055s057lbl.pdf#page=38."},{"key":"ref_44","unstructured":"(2025, December 28). Available online: https:\/\/go.drugbank.com\/drugs\/DB00472."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/dmd.105.004077","article-title":"In vitro- in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude","volume":"33","author":"Venkatakrishnan","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0090-9556(24)15222-1","article-title":"Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/00912700122010609","article-title":"P-glycoprotein interactions of nefazodone and trazodone in cell culture","volume":"41","author":"Perloff","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Petrucci, V., Dragone, P., Laurenti, M.C., Oggianu, L., Zabela, V., and Cattaneo, A. (2025). Characterization of trazodone metabolic pathways and species-specific profiles. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1636919"},{"key":"ref_49","unstructured":"(2025, December 28). Available online: https:\/\/go.drugbank.com\/drugs\/DB00285."},{"key":"ref_50","unstructured":"Electronic Medicines Compendium (2025, December 28). Summary of Product Characteristics Efexor XL. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/1219\/smpc#gref."},{"key":"ref_51","unstructured":"Electronic Medicines Compendium (2025, December 28). Summary of Product Characteristics Amitriptyline. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/10849\/smpc#gref."},{"key":"ref_52","unstructured":"Almasi, A., Patel, P., and Meza, C.E. (2025, December 16). Doxepin. StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542306\/."},{"key":"ref_53","unstructured":"(2025, December 28). Available online: https:\/\/www.clinpgx.org\/drug\/PA449969\/summaryAnnotation."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-3565(25)20103-3","article-title":"Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers","volume":"278","author":"Koyama","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_55","unstructured":"Electronic Medicines Compendium (2025, December 28). Summary of Product Characteristics Manerix. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/10614\/smpc#gref."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/bph.14936","article-title":"Clinical relevance of St. John\u2019s wort drug interactions revisited","volume":"177","author":"Nicolussi","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_57","unstructured":"European Medicines Agency (2025, December 28). Summary of Product Characteristics Abilify. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abilify-maintena-epar-product-information_en.pdf."},{"key":"ref_58","unstructured":"Electronic Medicines Compendium (2025, December 28). Summary of Product Characteristics Clozaril. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/4411\/smpc#gref."},{"key":"ref_59","unstructured":"Electronic Medicines Compendium (2025, December 28). Summary of Product Characteristics Haloperidol. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/100315\/smpc#gref."},{"key":"ref_60","unstructured":"European Medicines Agency (2025, December 28). Summary of Product Characteristics Latuda. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/latuda-epar-product-information_en.pdf."},{"key":"ref_61","unstructured":"European Medicines Agency (2025, December 28). Summary of Product Characteristics Zyprexa. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zyprexa-epar-product-information_en.pdf."},{"key":"ref_62","unstructured":"European Medicines Agency (2025, December 28). Summary of Product Characteristics Xeplion. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeplion-epar-product-information_en.pdf."},{"key":"ref_63","unstructured":"European Medicines Agency (2025, December 28). Summary of Product Characteristics Seroquel. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/seroquel-seroquel-xr-and-associated-names-article-30-referral-annex-iii_en.pdf."},{"key":"ref_64","unstructured":"European Medicines Agency (2025, December 28). Summary of Product Characteristics Okedi. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/okedi-epar-product-information_en.pdf."},{"key":"ref_65","unstructured":"Centers for Disease Control and Prevention (2025, August 30). Global Viral Hepatitis, Available online: https:\/\/www.cdc.gov\/hepatitis\/global\/?CDC_AAref_Val."},{"key":"ref_66","first-page":"971","article-title":"Psychiatric side effects of pegylated interferon-\u03b1 and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis","volume":"16","author":"Davoodi","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E194765","DOI":"10.1001\/jamanetworkopen.2019.4765","article-title":"Assessing the Safety of Direct Acting Antiviral Agents for Hepatitis C","volume":"2","author":"McGlynn","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","article-title":"Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: High utilization of drugs with interaction potential","volume":"26","author":"Lauffenburger","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","article-title":"Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions","volume":"23","author":"Langness","year":"2017","journal-title":"World J. Gastroenterol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:27:12Z","timestamp":1767356832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/1\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ph19010087"],"URL":"https:\/\/doi.org\/10.3390\/ph19010087","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}